NCT03932955

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Study Evaluating the Efficacy and Safety of MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Peking University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory B-cell lymphoma.

Detailed description

In this single-center, open-label, nonrandomized, no control, prospective clinical trial, appoximately 15 relapsed or refractory B-cell lymphoma patients will be enrolled. Side effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with R/R B-cell lymphoma

Conditions

• Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	MC-19PD1 CAR-T cells	T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.

Timeline

• Start date: 2019-05-01
• Primary completion: 2021-05-01
• Completion: 2021-05-01
• First posted: 2019-05-01
• Last updated: 2019-05-01

Locations

1 site across 1 country: China